Signal mining and risk analysis of tisotumab vedotin adverse events based on the FAERS database
Abstract Tisotumab vedotin (TV), the first antibody–drug conjugate (ADC) targeting tissue factor, was granted approval by the Food and Drug Administration (FDA) for the treatment of recurrent or metastatic cervical cancer. However, its adverse events (AE) are mainly recorded in clinical trials, lack...
Zapisane w:
| Główni autorzy: | , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Nature Portfolio
2025-08-01
|
| Seria: | Scientific Reports |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1038/s41598-025-14710-9 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|